Clinical Trials Logo
  1. Home
  2. Tuberous Sclerosis
  3. NCT02104011

Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers — STBETA  

Tuberous Sclerosis Clinical Trial

Official title:
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial

Clinical Trial Summary

Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization. Development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors. Angiomyolipomas have been shown to regress after prolonged treatment with mTOR inhibitors (Sirolimus), but with a large proportion of secondary effects. We showed recently that beta-blockers were able to induce regression of infantile hemagiomas. Consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the presence of beta2 receptors.

The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02104011
Study type Interventional
Source University Hospital, Bordeaux
Contact
Status Completed
Phase Phase 2
Start date May 22, 2015
Completion date November 22, 2017
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Recruiting NCT03422367 - JASPER Early Intervention for Tuberous Sclerosis N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Recruiting NCT02461459 - Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Completed NCT01526356 - Topical Rapamycin to Erase Angiofibromas in TSC Phase 2
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Terminated NCT01092208 - Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Active, not recruiting NCT01954693 - A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Phase 2
Completed NCT03826628 - Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Phase 2/Phase 3
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT05286632 - KidneYou - Innovative Digital Therapy N/A
Withdrawn NCT04344626 - Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery N/A
Recruiting NCT05199402 - Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Recruiting NCT00001975 - Study of Skin Tumors in Tuberous Sclerosis